ClinicalTrials.gg
RecruitingNCT06456450TARGETUpdated May 19, 2026

Taiwan Severe Asthma Biologic Registry

An observational study in Pulmonary Disease and Asthma, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Primary conditionAsthmaRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Asthma
Why
  1. The study's listed conditions name Asthma, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Taichung Veterans General Hospital · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.

Planned enrollment
4th of 16
500 · median 225
Started
2023
with 8 others
Observational
16 of 88
5 open now
Primary completion
2043-02
later than 17 of 17 live
Registered
79th of 88
by date

Among the 88 studies in Asthma with a site in Taiwan, this one is the 4th largest by planned enrollment of the 16 observational ones that give a count, is one of 9 that started in 2023, is one of 16 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 79th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Asthma with a site in Taiwan, or all of them as a file.
02

Study summary

This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.

The goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients.

The main question[s] it aims to answer are:

  1. Determine risk factors associated with poor asthma control.
  2. Support the development of effectiveness and safety of therapeutic principles
  3. To discover the real-world effectiveness of different biologics ( Clinical remission)
  4. To discover the impact of initiating biologics for severe asthma patients.
  5. To evaluate the prevalence of biologics switching and its benefits for patients.
  6. To compare the achievement rate of clinical remission among different biologics.

Participants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.

03

Conditions studied

  • Pulmonary Disease
  • Asthma

Browse trials for

Keywords

  • Severe Asthma
  • Registry
  • Biologic
04

In context

Asthma Reclassified

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

This study's planned enrollment of 500 is above the median of 159 across 1,254 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Taichung Veterans General Hospital is the lead sponsor of 176 studies on the registry; 38 are open to participants now.

Compared within Asthma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Severe Asthma Patient

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures.
  • Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case.
  • Female and male aged over 18 years old.
  • Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020.

Exclusion criteria

Exclusion Criteria:

  • Lack of for participation.
  • History of Biologic usage before January 1, 2020, should be ruled out.
  • The should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation.
  • Comorbid pulmonary diseases (e.g.: , Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Omalizumab

    Severe asthma patients who are treated with omalizumab after January 1, 2020.

    Biological: Biological Treatment for severe asthma patients

  • Mepolizumab

    Severe asthma patients who are treated with mepolizumab after January 1, 2020.

    Biological: Biological Treatment for severe asthma patients

  • Benralizumab

    Severe asthma patients who are treated with benralizumab after January 1, 2020.

    Biological: Biological Treatment for severe asthma patients

  • Dupilzumab

    Severe asthma patients who are treated with dupilzumab after January 1, 2020.

    Biological: Biological Treatment for severe asthma patients

  • Tezepelumab

    Severe asthma patients who are treated with Tezepelumab after January 1, 2020.

    Biological: Biological Treatment for severe asthma patients

Interventions

  • BiologicalOmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

    Also known as: Omalizumab, Mepolizumab, Benralizumab, Dupilzumab, Tezepelumab

07

What researchers measure

Primary outcomes

  1. Status of Asthma Control

    Mean change in Asthma Control Test score after biologic initiation.

    Time frame: 6 months

  2. Status of Asthma exacerbations

    Annual frequency of exacerbations after biologic initiation.

    Time frame: 6 months

  3. Reduction of daily oral corticosteriod dose

    Percentage of daily oral corticosteroids dose reduction after biologic initiation.

    Time frame: 6 months

  4. Change of Pre-BD FEV1 (%pred)

    Measure the change of Pre-BD FEV1 (%pred) after biologic initiation. FVC (L) FEV1(L)

    Time frame: 6 months

Secondary outcomes

  1. Disease Prognosis

    1. Describe the Cross-sectional phenotypic or pathophysiological (endotype) characteristics of poor asthma control. 2. Describe the natural history, intervention responsiveness and long-term prognosis of severe asthma.

    Time frame: 6 months

  2. Mortality

    Define the mortality rate of the study cohort

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2043, 231 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 231 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 13, 2024
StartActual
Nov 11, 2023
Primary completionEst.
Feb 28, 2043
CompletionEst.
Feb 28, 2043
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06456450
Collaborators
E-DA Hospital, National Cheng-Kung University Hospital, National Yang Ming Chiao Tung University Hospital, Chang Gung Memorial Hospital
Responsible party
Pin-Kuei Fu, MD, PhD (Director of Clinical Trail Center, Taichung Veterans General Hospital) — Principal investigator
First posted
Jun 13, 2024
Start date
Nov 11, 2023
Primary completion
Feb 28, 2043 (estimated)
Completion
Feb 28, 2043 (estimated)
Last update
May 19, 2026

Study contacts

Pin-Kuei Fu, MD.,PhD.
Contact
yetquen@gmail.com
886-4-23592525 ext. 6535

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion